Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -6.81% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 5.21% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 92.37% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -84.64% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 95.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 327.74% |
| Mar 31, 2026 | 1,228.66% |
| Dec 31, 2025 | 233.17% |
| Sep 30, 2025 | 362.33% |
| Jun 30, 2025 | -327.66% |
| Mar 31, 2025 | 72.32% |
| Dec 31, 2024 | 39.24% |
| Sep 30, 2024 | -175.51% |
| Jun 30, 2024 | 93.88% |
| Mar 31, 2024 | 62.13% |
| Dec 31, 2023 | 33.55% |
| Sep 30, 2023 | 136.40% |
| Jun 30, 2023 | 0.50% |
| Mar 31, 2023 | 27.56% |
| Dec 31, 2022 | 19.72% |
| Sep 30, 2022 | -98.48% |
| Jun 30, 2022 | -46.34% |
| Mar 31, 2022 | -20.00% |
| Dec 31, 2021 | -6.13% |
| Sep 30, 2021 | 19.26% |